IDT Biologika GmbH

Dessau-Rosslau, Germany
Viral Vaccines (Live & Attenuated) Viral Vectors (AAV, Lentiviral, Adenoviral) Cell & Gene Therapeutics Oncolytic Viruses Recombinant Proteins / Biologics Monoclonal Antibodies Sterile Injectable Fill-Finish (Aseptic Liquid, Lyophilization, Pre-filled Syringes)
1 confirmed programs · 1 sponsors
56.2
Signal Score
○ FDA Inspections ✓ Clinical Trials (1) ○ SEC Filings ✓ Press (7) ○ EMA GMP ○ MHRA GMP

Quick Facts: IDT Biologika GmbH

Signal Score
56.2/100
Quality Compliance
Assessment pending
Headquarters
Dessau-Rosslau, Germany
Modalities
Viral Vaccines (Live & Attenuated), Viral Vectors (AAV, Lentiviral, Adenoviral), Cell & Gene Therapeutics, Oncolytic Viruses, Recombinant Proteins / Biologics, Monoclonal Antibodies, Sterile Injectable Fill-Finish (Aseptic Liquid, Lyophilization, Pre-filled Syringes)
Active Programs
1 confirmed from ClinicalTrials.gov across 1 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 50.0
1 active programs across 1 sponsors
Modalities: Monoclonal Antibodies, Oncolytic Viruses, Cell & Gene Therapeutics, Sterile Injectable Fill-Finish (Aseptic Liquid, Lyophilization, Pre-filled Syringes), Recombinant Proteins / Biologics, Viral Vectors (AAV, Lentiviral, Adenoviral), Viral Vaccines (Live & Attenuated)
Source: ClinicalTrials.gov
1 active programs across 1 sponsors · Modalities: Monoclonal Antibodies, Oncolytic Viruses, Cell & Gene Therapeutics, Sterile Injectable Fill-Finish (Aseptic Liquid, Lyophilization, Pre-filled Syringes), Recombinant Proteins / Biologics, Viral Vectors (AAV, Lentiviral, Adenoviral), Viral Vaccines (Live & Attenuated)
Programs 1
Sponsors1
ModalitiesViral Vaccines (Live & Attenuated), Viral Vectors (AAV, Lentiviral, Adenoviral), Cell & Gene Therapeutics, Oncolytic Viruses, Recombinant Proteins / Biologics, Monoclonal Antibodies, Sterile Injectable Fill-Finish (Aseptic Liquid, Lyophilization, Pre-filled Syringes)
1 active programs across 1 sponsors
Modalities: Monoclonal Antibodies, Oncolytic Viruses, Cell & Gene Therapeutics, Sterile Injectable Fill-Finish (Aseptic Liquid, Lyophilization, Pre-filled Syringes), Recombinant Proteins / Biologics, Viral Vectors (AAV, Lentiviral, Adenoviral), Viral Vaccines (Live & Attenuated)
Source: ClinicalTrials.gov facility matching
NCT04119440 Safety and Immunogenicity of the Candidate Vaccine... PHASE1 Completed
Source: ClinicalTrials.gov · Retrieved Apr 08, 2026
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (7 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press7 articles
Broad modality coverage (7 modalities)

Clinical Activity 1 studies

NCT04119440 Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS PHASE1 Completed
Source: ClinicalTrials.gov · Retrieved Apr 08, 2026

Recent News 7 articles

news Wed, 05 No
IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive participation in WVC, CPHI and BIO-Europe 2025 - prnewswire.com
Source →
news Tue, 27 Fe
Takeda taps Biological E to ⁠ramp up Qdenga manufacturing capacity on quest to make 100M doses a year - Fierce Pharma
Source →
news Tue, 21 Oc
From the experts: How to successfully implement Annex 1 regulations - Pharmaceutical Technology
Source →
news Thu, 27 Ju
SK Bioscience begins 'globalization' push, paying $244M for majority stake in contract manufacturer IDT Biologika - Fierce Pharma
Source →
news Thu, 27 Ju
SK Bioscience to buy German vaccine maker IDT Biologika for $244 mn - KED Global
Source →
news Thu, 27 Ju
IDT Biologika Acquired for $244M by SK Bioscience to Fuel Global Expansion - BioBuzz
Source →
news Mon, 01 Ju
SK Bioscience Acquires Majority Stake in IDT Biologika - CHEManager
Source →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Viral Vaccines (Live & Attenuated) CDMOs → Viral Vectors (AAV, Lentiviral, Adenoviral) CDMOs → Cell & Gene Therapeutics CDMOs → Oncolytic Viruses CDMOs → Recombinant Proteins / Biologics CDMOs → Monoclonal Antibodies CDMOs → Sterile Injectable Fill-Finish (Aseptic Liquid, Lyophilization, Pre-filled Syringes) CDMOs →